346 related articles for article (PubMed ID: 21118480)
1. Long-term survival of women with basal-like ductal carcinoma in situ of the breast: a population-based cohort study.
Zhou W; Jirström K; Johansson C; Amini RM; Blomqvist C; Agbaje O; Wärnberg F
BMC Cancer; 2010 Nov; 10():653. PubMed ID: 21118480
[TBL] [Abstract][Full Text] [Related]
2. Molecular phenotypes of DCIS predict overall and invasive recurrence.
Williams KE; Barnes NLP; Cramer A; Johnson R; Cheema K; Morris J; Howe M; Bundred NJ
Ann Oncol; 2015 May; 26(5):1019-1025. PubMed ID: 25678586
[TBL] [Abstract][Full Text] [Related]
3. Molecular subtypes in ductal carcinoma in situ of the breast and their relation to prognosis: a population-based cohort study.
Zhou W; Jirström K; Amini RM; Fjällskog ML; Sollie T; Lindman H; Sørlie T; Blomqvist C; Wärnberg F
BMC Cancer; 2013 Oct; 13():512. PubMed ID: 24171825
[TBL] [Abstract][Full Text] [Related]
4. Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis.
Kerlikowske K; Molinaro AM; Gauthier ML; Berman HK; Waldman F; Bennington J; Sanchez H; Jimenez C; Stewart K; Chew K; Ljung BM; Tlsty TD
J Natl Cancer Inst; 2010 May; 102(9):627-37. PubMed ID: 20427430
[TBL] [Abstract][Full Text] [Related]
5. Biologic behavior and long-term outcomes of breast ductal carcinoma in situ with microinvasion.
Fang Y; Wu J; Wang W; Fei X; Zong Y; Chen X; Huang O; He J; Chen W; Li Y; Shen K; Zhu L
Oncotarget; 2016 Sep; 7(39):64182-64190. PubMed ID: 27577080
[TBL] [Abstract][Full Text] [Related]
6. The prognostic role of HER2 expression in ductal breast carcinoma in situ (DCIS); a population-based cohort study.
Borgquist S; Zhou W; Jirström K; Amini RM; Sollie T; Sørlie T; Blomqvist C; Butt S; Wärnberg F
BMC Cancer; 2015 Jun; 15():468. PubMed ID: 26062614
[TBL] [Abstract][Full Text] [Related]
7. Tumor thickness and histological features as predictors of invasive foci within preoperatively diagnosed ductal carcinoma in situ.
Mori K; Takeda M; Kodama Y; Kiyokawa H; Yasojima H; Mizutani M; Otani Y; Morikawa N; Masuda N; Mano M
Hum Pathol; 2017 Jun; 64():145-155. PubMed ID: 28434924
[TBL] [Abstract][Full Text] [Related]
8. HER2/neu and Ki-67 expression predict non-invasive recurrence following breast-conserving therapy for ductal carcinoma in situ.
Rakovitch E; Nofech-Mozes S; Hanna W; Narod S; Thiruchelvam D; Saskin R; Spayne J; Taylor C; Paszat L
Br J Cancer; 2012 Mar; 106(6):1160-5. PubMed ID: 22361634
[TBL] [Abstract][Full Text] [Related]
9. Lectin histochemistry reveals SNA as a prognostic carbohydrate-dependent probe for invasive ductal carcinoma of the breast: a clinicopathological and immunohistochemical auxiliary tool.
dos-Santos PB; Zanetti JS; Vieira-de-Mello GS; Rêgo MB; Ribeiro-Silva A A; Beltrão EI
Int J Clin Exp Pathol; 2014; 7(5):2337-49. PubMed ID: 24966944
[TBL] [Abstract][Full Text] [Related]
10. Beta 1 integrin predicts survival in breast cancer: a clinicopathological and immunohistochemical study.
dos Santos PB; Zanetti JS; Ribeiro-Silva A; Beltrão EI
Diagn Pathol; 2012 Aug; 7():104. PubMed ID: 22894137
[TBL] [Abstract][Full Text] [Related]
11. Risk of subsequent in situ and invasive breast cancer in human epidermal growth factor receptor 2-positive ductal carcinoma in situ.
Curigliano G; Disalvatore D; Esposito A; Pruneri G; Lazzeroni M; Guerrieri-Gonzaga A; Luini A; Orecchia R; Goldhirsch A; Rotmensz N; Bonanni B; Viale G
Ann Oncol; 2015 Apr; 26(4):682-687. PubMed ID: 25600567
[TBL] [Abstract][Full Text] [Related]
12. Expression of HAb18G is associated with tumor progression and prognosis of breast carcinoma.
Liu F; Cui L; Zhang Y; Chen L; Wang Y; Fan Y; Lei T; Gu F; Lang R; Pringle GA; Zhang X; Chen Z; Fu L
Breast Cancer Res Treat; 2010 Dec; 124(3):677-88. PubMed ID: 20213083
[TBL] [Abstract][Full Text] [Related]
13. Molecular subtypes of ductal carcinoma in situ in African American and Caucasian American women: distribution and correlation with pathological features and outcome.
Sharaf Aldeen B; Feng J; Wu Y; Nassar Warzecha H
Cancer Epidemiol; 2013 Aug; 37(4):474-8. PubMed ID: 23639792
[TBL] [Abstract][Full Text] [Related]
14. Basal-like immunophenotype markers and prognosis in early breast cancer.
Cassol L; Silveira Graudenz M; Zelmanowicz A; Cancela A; Werutsky G; Rovere RK; Garicochea B
Tumori; 2010; 96(6):966-70. PubMed ID: 21388060
[TBL] [Abstract][Full Text] [Related]
15. Hormonal receptor status, Ki-67 and HER2 expression: Prognostic value in the recurrence of ductal carcinoma in situ of the breast?
Poulakaki N; Makris GM; Battista MJ; Böhm D; Petraki K; Bafaloukos D; Sergentanis TN; Siristatidis C; Chrelias C; Papantoniou N
Breast; 2016 Feb; 25():57-61. PubMed ID: 26612082
[TBL] [Abstract][Full Text] [Related]
16. Breast ductal Carcinoma in situ associated with microinvasion induces immunological response and predicts ipsilateral invasive recurrence.
Chen XY; Thike AA; Koh VCY; Nasir NDM; Bay BH; Tan PH
Virchows Arch; 2021 Apr; 478(4):679-686. PubMed ID: 33140128
[TBL] [Abstract][Full Text] [Related]
17. Subtypes of high-grade breast ductal carcinoma in situ (DCIS): incidence and potential clinical impact.
Schandiz H; Park D; Kaiser YL; Lyngra M; Talleraas IS; Geisler J; Sauer T
Breast Cancer Res Treat; 2023 Sep; 201(2):329-338. PubMed ID: 37453021
[TBL] [Abstract][Full Text] [Related]
18. A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast.
Solin LJ; Gray R; Baehner FL; Butler SM; Hughes LL; Yoshizawa C; Cherbavaz DB; Shak S; Page DL; Sledge GW; Davidson NE; Ingle JN; Perez EA; Wood WC; Sparano JA; Badve S
J Natl Cancer Inst; 2013 May; 105(10):701-10. PubMed ID: 23641039
[TBL] [Abstract][Full Text] [Related]
19. Keratin 17 is overexpressed and predicts poor survival in estrogen receptor-negative/human epidermal growth factor receptor-2-negative breast cancer.
Merkin RD; Vanner EA; Romeiser JL; Shroyer ALW; Escobar-Hoyos LF; Li J; Powers RS; Burke S; Shroyer KR
Hum Pathol; 2017 Apr; 62():23-32. PubMed ID: 27816721
[TBL] [Abstract][Full Text] [Related]
20. Expression profiling of in vivo ductal carcinoma in situ progression models identified B cell lymphoma-9 as a molecular driver of breast cancer invasion.
Elsarraj HS; Hong Y; Valdez KE; Michaels W; Hook M; Smith WP; Chien J; Herschkowitz JI; Troester MA; Beck M; Inciardi M; Gatewood J; May L; Cusick T; McGinness M; Ricci L; Fan F; Tawfik O; Marks JR; Knapp JR; Yeh HW; Thomas P; Carrasco DR; Fields TA; Godwin AK; Behbod F
Breast Cancer Res; 2015 Sep; 17():128. PubMed ID: 26384318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
